Risk-adapted survival analysis. The estimated 12-year EFS (A), OS (B) for all 265 patients, and the 12-year DFS (C) for 245 patients in CR, showing significant difference between low-to-intermediate–risk and high-risk patients (P = .002, .008, and .001, respectively).